Anesth Pain Med Search


Neuromuscular Physiology and Pharmacology
Anesthesia and Pain Medicine 2011;6(4):307-313.
Published online October 31, 2011.
Clinical use of sugammadex
Kyo Sang Kim
Department of Anesthesiology and Pain Medicine, College of Medicine, Hanyang University, Seoul, Korea.
An ideal reversal agent could be given at any time after the administration of a neuromuscular blocking agent, and should have no muscarinic side-effects. Sugammadex is a modified gamma-cyclodextrin designed to encapsulate rocuronium bromide, providing a rapid reversal of neuromuscular blockade. Sugammadex is a revolutionary investigational reversal drug currently undergoing Phase III testing whose introduction into clinical practice in Korea may change the face of clinical neuromuscular pharmacology. The dose of sugammadex for reversal of moderate block (when T2 is detectable) is approximately 2 mg/kg, the dose is 4-8 mg/kg for profound block (post-tetanic count 1-2) and a larger dose of 16 mg/kg for immediate reversal. The use of sugammadex has not been reported to be associated with recurrence of block provided a dose that is adequate for reversal has been used. Sugammadex appears to have an acceptable safety profile. Volatile agent such as sevoflurane seems not to influence the sugammadex ability to reverse the rocuronium neuromuscular blockade.
Key Words: Neuromuscular block antagonists, Sugammadex
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 1,154 View
  • 17 Download
Related articles in Anesth Pain Med

Advantages and pitfalls of clinical application of sugammadex2020 July;15(3)

The potential risks of sugammadex2019 April;14(2)

Article category

Browse all articles >


Browse all articles >

Editorial Office
101-3503, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-792-5128    Fax: +82-2-792-4089    E-mail:                

Copyright © 2024 by Korean Society of Anesthesiologists.

Developed in M2PI

Close layer
prev next